<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-4004</journal-id>
<journal-title><![CDATA[Vitae]]></journal-title>
<abbrev-journal-title><![CDATA[Vitae]]></abbrev-journal-title>
<issn>0121-4004</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Química Farmacéutica, Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-40042016000200119</article-id>
<article-id pub-id-type="doi">10.17533/udea.vitae.v23n2a04</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[ASSESMENT OF PLTELET ANTIAGGREGANT ACTIVITY OF A FRACTION FROM AN ETHANOLIC EXTRACT OF THE BARK OF Nectandra amazonum Nees]]></article-title>
<article-title xml:lang="es"><![CDATA[EVALUACIÓN DE LA ACTIVIDAD ANTIAGREGANTE PLAQUETARIA DE UNA FRACCIÓN DEL EXTRACTO ETANÓLICO DE CORTEZA DE Nectandra amazonum Nees]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[ESPITIA CORREDOR]]></surname>
<given-names><![CDATA[Jenaro Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[CUCA SUÁREZ]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[GUERRERO PABÓN]]></surname>
<given-names><![CDATA[Mario Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Ciencias Departamento de Farmacia]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Ciencias Departamento de Química]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>05</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>05</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<numero>2</numero>
<fpage>119</fpage>
<lpage>123</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-40042016000200119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-40042016000200119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-40042016000200119&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: Some species of the Lauraceae family are known to produce secondary metabolites that have antiplatelet properties. Studies on the leaves of Nectandra amazonum Nees. have shown antiaggregant activity but the bark of this species has not been studied.  Objectives: To assess the antiplatelet effect of the ethanolic fraction obtained from the bark of Nectandra amazonum Nees. (N.V. &#8220;laurel amarillo&#8221;, Lauraceae) applying the &#8220;Born&#8221; turbidimetric method.  Methods:  The screening test compared the effects of a fraction of N. amazonum (0.1 mg/mL), acetylsalicylic acid (ASA, 0.5 mM, as reference standard) and dimethylsulphoxide (DMSO, 0.1%, as control) on human platelets stimulated with adenosine diphosphate (ADP, 2 &#956;M), epinephrine (EPI, 1 uM (one micromolar)), collagen (COLL, 1 &#956;g/mL) and arachidonic acid (AA, 0.2 mg/mL). Subsequently, the study focused on determining the antiaggregant potency of the N. amazonum fraction through concentration - response curves (from 1 &#956;g/mL to 0.4 mg/mL), obtaining pIC50 (-log IC50) values against the platelet agonists.  Results:  Control platelets attained the highest percentage values of aggregation (96% AA, 89% EPI, 85% COLL, and 77% ADP). The N. amazonum fraction significantly reduced the aggregation effects (6% AA, 45% EPI, 10% COLL, 21% ADP), with values close to those obtained with ASA (17% AA, 21% EPI, 10% COLL, 20% ADP). According to concentration - response curves, the pIC50 values of the ethanolic fraction indicated the following order of potency: AA, 4.90 &gt; ADP, 4.51 &gt; COLL, 4.33 &gt; EPI, 3.85.  Conclusions:  These results suggest that the N. amazonum Nees. ethanolic fraction elicited antiplatelet effects mainly related to the inhibition of the arachidonic acid pathway.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Antecedentes:  Algunas especies de la familia Lauraceae poseen metabolitos secundarios que ejercen efectos antiplaquetarios. Estudios de las hojas de Nectandra amazonum Nees. han mostrado esa actividad, pero no se conoce sobre las propiedades antiagregantes de su corteza.  Objetivos:  Evaluar el efecto antiagregante plaquetario de la fracción etanólica obtenida de la corteza de Nectandra amazonum Nees. (N.V. &#8220;laurel amarillo&#8221;, Lauraceae) aplicando el método turbidimétrico de Born.  Métodos:  En el tamizaje antiagregante se comparó la fracción de N. amazonum (0,1 mg/mL) con ácido acetil salicílico (ASA 0,5 mM, como estándar de referencia) y dimetilsulfóxido (DMSO, 0,1%, como control) en plaquetas humanas estimuladas con adenosin difosfato (ADP, 2 &#956;M), epinefrina (EPI, 1 uM (uno micromolar)), colágeno (COLL, 1 &#956;g/mL) y ácido araquidónico (AA, 0,2 mg/mL). Posteriormente, el estudio se enfocó en la determinación de la potencia antiagregante de la fracción mediante curvas de concentración - respuesta (desde 1 &#956;g/mL hasta 0,4 mg/mL) para obtener los valores respectivos de pIC50 (-log CI50).  Resultados:  En el grupo control se alcanzaron altos valores de agregación plaquetaria (96% AA, 89% EPI, 85% COLL, 77% ADP). La fracción de N. amazonum redujo significativamente la agregación (6% AA, 45% EPI, 10% COLL, 21% ADP), con valores próximos a los obtenidos con ASA (17% AA, 21% EPI, 10% COLL, 20% ADP). De acuerdo con las curvas de concentración - respuesta, los valores de pIC50 arrojaron el siguiente orden de potencia: AA, 4,90 &gt; ADP, 4,51 &gt; COLL, 4,33 &gt; EPI, 3,85.  Conclusiones:  Estos resultados sugieren que la fracción etanólica de N. amazonum Nees ejerce efectos antiplaquetarios relacionados especialmente con la cascada metabólica del ácido araquidónico..]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Lauraceae]]></kwd>
<kwd lng="en"><![CDATA[platelet aggregation]]></kwd>
<kwd lng="en"><![CDATA[arachidonic acid]]></kwd>
<kwd lng="en"><![CDATA[adenosine diphosphate]]></kwd>
<kwd lng="en"><![CDATA[epinephrine]]></kwd>
<kwd lng="en"><![CDATA[collagen]]></kwd>
<kwd lng="es"><![CDATA[Lauraceae]]></kwd>
<kwd lng="es"><![CDATA[agregación plaquetaria]]></kwd>
<kwd lng="es"><![CDATA[ácido araquidónico]]></kwd>
<kwd lng="es"><![CDATA[adenosin difosfato]]></kwd>
<kwd lng="es"><![CDATA[epinefrina]]></kwd>
<kwd lng="es"><![CDATA[colágeno]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[Global Atlas on Cardiovascular Disease Prevention and Control.]]></source>
<year>2011</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[Noncommunicable Diseases (NCD) Country Profiles, Colombia]]></source>
<year>2014</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Changes in cardiovascular risk factors in developing countries]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fourcade]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Trop]]></source>
<year>2007</year>
<volume>67</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>552-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of anti-thrombotic therapy in coronary artery disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sudo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hirayama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Nihon Rinsho]]></source>
<year>2014</year>
<volume>72</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1276-81</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Atherosclerosis: from biology to pharmacological treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riccioni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sblendorio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[J Geriatr Cardiol]]></source>
<year>2012</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>305-17</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Natural products for antithrombosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[FQ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[FQ]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[ZN]]></given-names>
</name>
</person-group>
<source><![CDATA[Evid Based Complement Alternat Med]]></source>
<year>2015</year>
<volume>876426</volume>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballabeni]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tognolini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bertoni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Barocelli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Res]]></source>
<year>2007</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ben Amor]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bouaziz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Romera-Castillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Salido]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Linares- Palomino]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bartegi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salido]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosado]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Med Chem]]></source>
<year>2007</year>
<volume>50</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>3937-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of butanolides from Cinnamomum tenuifolium on platelet aggregation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecules]]></source>
<year>2013</year>
<volume>18</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>11836-41</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nectandra amazonum-derived flavonoids as COX-1 inhibitors: in vitro and docking studies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdés-Barrera]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Cuca-Suarez]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Coy-Barrera]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Prod Commun]]></source>
<year>2014</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>649-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coy]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Cuca]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Sef kow]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioorg Med Chem Lett]]></source>
<year>2009</year>
<volume>19</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>6922-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Three New 7.3,8.5-Connected Bicyclo(3.2.1) octanoids and Other Neolignans from Leaves of Nectandra amazonum Nees. (Lauraceae)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coy]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Cuca]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<source><![CDATA[Chem Pharm Bull]]></source>
<year>2009</year>
<volume>57</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>639- 642</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Discovery and evaluation, Pharmacological assays]]></source>
<year>2002</year>
<edition>2nd ed</edition>
<page-range>280-282 p</page-range><publisher-loc><![CDATA[Berlin Heidelberg New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noubiap]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nansseu]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Vasc Health Risk Manag]]></source>
<year>2015</year>
<volume>25</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>503-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lalor]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Elissamburu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Filipini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Conde]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cura]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Trivi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina]]></source>
<year>2015</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>207-12</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
